


Gastrazole

Cat. No.:	HY-19445
CAS No.:	862583-15-1
Molecular Formula:	C ₃₄ H ₃₂ FN ₅ Na ₂ O ₇
Molecular Weight:	687.63
Target:	Cholecystokinin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Gastrazole (JB95008) is potent and selective CCK2/gastrin receptor antagonist. Gastrazole can decrease the level of gastric acid. Gastrazole inhibits the Gastrin-stimulated growth of pancreatic cancer ^{[1][2]} .	
IC₅₀ & Target	CCKBR	
In Vivo	Gastrazole (0.15-3 μmol/kg; i.v.) dose-dependently inhibits the Pentagastrin-stimulated gastric acid secretion ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Male Sprague-Dawley rats with a gastric fistula ^[2]
	Dosage:	0.15, 0.3, 3 mg/kg
	Administration:	Intravenous administration
	Result:	Dose-dependently inhibited Pentagastrin-stimulation acid secretion by maximally 73%.

REFERENCES

- [1]. Chau I, et, al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. *Br J Cancer*. 2006 Apr 24;94(8):1107-15.
- [2]. Rudholm T, et, al. Release of regulatory gut peptides somatostatin, neurotensin and vasoactive intestinal peptide by acid and hyperosmolal solutions in the intestine in conscious rats. *Regul Pept*. 2009 Jan 8;152(1-3):8-12.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA